Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus YAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus YAZ.
NORLESTRIN 21 2.5/50 vs YAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Combination of ethinyl estradiol and drospirenone; suppresses gonadotropins (FSH and LH) inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration. Drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
One tablet (0.02 mg ethinyl estradiol and 3 mg drospirenone) orally once daily for 24 days, followed by 2 days of placebo.
None Documented
None Documented
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Terminal elimination half-life of drospirenone is 31.2-32.5 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 10 days of daily dosing. Clinically, once-daily dosing maintains stable concentrations.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Approximately 50% of drospirenone is excreted renally (metabolites, with <10% unchanged), and 50% via feces (biliary) after hepatic conjugation. Ethinyl estradiol is primarily excreted renally (60%) and fecally (40%) as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive